30-Second Takeaway
- Morning anti–PD-1 chemoimmunotherapy nearly doubled PFS and markedly improved OS in advanced NSCLC without added toxicity.
- Higher PM2.5 exposure in CF was linked to steeper ppFEV1 decline, especially in children and severe genotypes.
- Quit-years meaningfully delay lung cancer risk, supporting later, risk-adapted LDCT starting ages for many former heavy smokers.
Week ending February 7, 2026
Timing, environment, and precision risk tools reshape pulmonary practice across oncology, CF, PAH, COPD, RSV, and neonatal lung disease
Morning anti–PD-1 chemoimmunotherapy substantially improves outcomes in advanced NSCLC
In treatment-naive stage IIIC–IV NSCLC without driver mutations, early-day anti–PD-1 immunochemotherapy markedly improved survival versus late-day dosing. Median PFS was 11.3 months with infusions before 15:00 versus 5.7 months after 15:00 (HR 0.40; 95% CI 0.29–0.55). Median OS was 28.0 versus 16.8 months for early versus late treatment (HR 0.42; 95% CI 0.29–0.60). Overall and immune-related toxicities were similar between schedules, removing safety as a rationale for late-day dosing. Early dosing increased circulating CD8+ T cells and the activated-to-exhausted CD8+ ratio over initial cycles. These findings support preferential morning scheduling of the first four anti–PD-1 chemoimmunotherapy cycles in eligible advanced NSCLC patients.
Higher PM2.5 exposure accelerates lung function decline in London cystic fibrosis patients
This longitudinal UK CF Registry analysis linked modeled residential air pollution to ppFEV1 decline over 10 years in 393 London CF patients. High PM2.5 exposure tertile was associated with a steeper adjusted ppFEV1 decline than the low-exposure tertile over the study period. Associations with NO2 exposure were less consistent than for PM2.5. Children and individuals with severe CF genotypes appeared particularly vulnerable to pollution-related lung function loss. Over 40% resided in the most deprived national quintile, underscoring environmental inequity in CF outcomes. Clinically, results support systematic air-quality counseling and advocacy as part of longitudinal CF management.
Quit-years substantially postpone lung cancer risk and screening-eligible ages in heavy smokers
Using UK Biobank data from 86,035 heavy smokers, this cohort quantified how smoking cessation duration postpones lung cancer risk. Risk postponement periods were 2.7, 6.2, 10.4, and 17.1 years for ≤5, 6–10, 11–15, and >15 quit-years, respectively. If current heavy smokers start LDCT at 50, equivalent risk levels for former smokers may occur roughly between 53 and 67 years. Many former heavy smokers could therefore begin screening later than 50, depending on quit-years and pack-years. Findings provide an empirical basis for quit-year–adapted LDCT starting ages rather than a rigid 15-year cessation cutoff.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.